Utilization, safety, and outcome of statin therapy in patients receiving immune checkpoint inhibitors

Background Immune checkpoint inhibitors (ICI) are an expanding class of cancer therapies that have been associated with cardiotoxicity. Whether cardiovascular risk-reducing medications like statins can safely or should be used in patients with cancer receiving ICI is not well-defined. Methods In a retrospective cohort study of 5796 cancer patients receiving ICI (2015–2024), we identified statin use via prescription data and determined statin indications based on American College of Cardiology/American Heart Association (ACC/AHA) guidelines. We conducted chart review to investigate statin discontinuation and the incidence of ICI-associated myositis and hepatitis. We used multivariable Cox proportional hazards models and landmark analysis to assess the associations between statin use and outcomes including acute coronary syndrome (ACS) and all-cause mortality. Results Despite statin indications at ICI initiation, 937/2058 (46%) were untreated with statins. These untreated patients were more likely to be younger, of Hispanic/Latino ethnicity, have a higher Area Deprivation Index, and have diabetes mellitus, compared to patients on statins ( n = 1121). Rates of ICI-associated myositis and hepatitis were not statistically different between the statin-treated and statin-indicated groups ( p = 0.53 and 0.43, respectively). In the multivariable Cox proportional hazards models, statin use during ICI therapy had no statistically significant association with ACS (HR 1.13, CI 0.67–1.90), or death after 270 days of ICI initiation (HR 0.78, CI 0.55–1.09) in the secondary landmark analysis. Conclusion Nearly half of the patients receiving ICI with ACC/AHA statin indications were not on statin therapy, revealing significant underutilization. Statin therapy was not associated with an increased risk of ICI-associated myositis or hepatitis but was also not associated with improved cardiovascular or mortality outcomes in our study. Further studies are needed to investigate the safety and clinical outcomes of statins in patients on ICI.

Authors

Institutions

Publication Details

Journal
Cardio-Oncology
Published
2026-11-21
DOI
https://doi.org/10.1186/s40959-026-00604-w
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Utilization, safety, and outcome of statin therapy in patients receiving immune checkpoint inhibitors

Ashley F. Stein-Merlob, Alexandra Drakaki, Jeffrey Feng, Eric H. Yang et al.
Cardio-Oncology
Cancer, Lipids, and Metabolism
article

Utilization, safety, and outcome of statin therapy in patients receiving immune checkpoint inhibitors

Ashley F. Stein-Merlob, Alexandra Drakaki, Jeffrey Feng, Eric H. Yang, Melissa G. Lechner, Qicong Sheng, Elizabeth Hutchins, Kevin B. Muy, Rachel S Saganty, Zehua Feng
article en

Abstract

Background Immune checkpoint inhibitors (ICI) are an expanding class of cancer therapies that have been associated with cardiotoxicity. Whether cardiovascular risk-reducing medications like statins can safely or should be used in patients with cancer receiving ICI is not well-defined. Methods In a retrospective cohort study of 5796 cancer patients receiving ICI (2015–2024), we identified statin use via prescription data and determined statin indications based on American College of Cardiology/American Heart Association (ACC/AHA) guidelines. We conducted chart review to investigate statin discontinuation and the incidence of ICI-associated myositis and hepatitis. We used multivariable Cox proportional hazards models and landmark analysis to assess the associations between statin use and outcomes including acute coronary syndrome (ACS) and all-cause mortality. Results Despite statin indications at ICI initiation, 937/2058 (46%) were untreated with statins. These untreated patients were more likely to be younger, of Hispanic/Latino ethnicity, have a higher Area Deprivation Index, and have diabetes mellitus, compared to patients on statins ( n = 1121). Rates of ICI-associated myositis and hepatitis were not statistically different between the statin-treated and statin-indicated groups ( p = 0.53 and 0.43, respectively). In the multivariable Cox proportional hazards models, statin use during ICI therapy had no statistically significant association with ACS (HR 1.13, CI 0.67–1.90), or death after 270 days of ICI initiation (HR 0.78, CI 0.55–1.09) in the secondary landmark analysis. Conclusion Nearly half of the patients receiving ICI with ACC/AHA statin indications were not on statin therapy, revealing significant underutilization. Statin therapy was not associated with an increased risk of ICI-associated myositis or hepatitis but was also not associated with improved cardiovascular or mortality outcomes in our study. Further studies are needed to investigate the safety and clinical outcomes of statins in patients on ICI.

Cardio-Oncology
University of California, Los Angeles (US), California University of Science and Medicine (US), Charles R. Drew University of Medicine and Science (US)
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon